Moderna earns $12 billion from its Spikevax vaccine
The Moderna laboratory made a profit in the order of 12 billion dollars thanks to the sale of its spikevax vaccine, against Covid-19
The American laboratory Moderna closed 2021 with a net profit of 12,202 million dollars (10,982 million euros) compared to the losses of 747 million (672 million euros) that it recorded in the previous year, thanks to the millions of doses sold of Spikevax, your COVID-19 vaccine.
Between January and December, the firm invoiced 18,471 million (16,625 million euros), compared to the 803 million (723 million euros) that it entered in 2020. This change is due to the fact that the vaccines began to be marketed robustly in 2021.
Income from vaccines was 17,675 million (15,909 million euros), compared to 200 million (180 million euros) the previous year, while income from subsidies grew by 38.9 %, to 735 million dollars (€662 million).
The cost of goods sold was 2,617 million (2,356 million euros), practically without comparison with 2020 while selling expenses, general and administrative expenses multiplied by three, to 567 million (510 million euros). The research and development (R&D) item expanded by 45.3 %, to 1,991 million (1,792 million euros).
Only in the fourth quarter of the year, the laboratory registered net profits of 4,868 million (4,382 million euros), compared to losses of 272 million (245 million euros) the previous year. Turnover stood at 7,211 million (6,490 million euros), compared to 571 million (514 million euros) in the last quarter of 2020.
Source: dpa
